{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
soravtansine
to a specific field?
There is one exact (name or code) match for soravtansine
Status:
Investigational
Source:
USAN:SORAVTANSINE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Soravtansine (DM4-SULFO-TBA), a maytansinoid derivative, is an antineoplastic agent. Antibody–maytansinoid conjugates (like Mirvetuximab soravtansine) are in clinical trials for the treatment of various cancers. Thus, Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate (ADC) that targets FRα (folate receptor alpha) for tumor-directed delivery of the maytansinoid DM4, a potent agent that induces mitotic arrest by suppressing microtubule dynamics.
Showing 1 - 6 of 6 results
Status:
Investigational
Source:
USAN:SORAVTANSINE [USAN]
Source URL:
Class (Stereo):
CHEMICAL (EPIMERIC)
Soravtansine (DM4-SULFO-TBA), a maytansinoid derivative, is an antineoplastic agent. Antibody–maytansinoid conjugates (like Mirvetuximab soravtansine) are in clinical trials for the treatment of various cancers. Thus, Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate (ADC) that targets FRα (folate receptor alpha) for tumor-directed delivery of the maytansinoid DM4, a potent agent that induces mitotic arrest by suppressing microtubule dynamics.
Status:
US Approved Rx
(2022)
Source:
BLA761310
(2022)
Source URL:
First approved in 2022
Source:
BLA761310
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02529553: Phase 1 Interventional Completed Advanced Cancer
(2015)
Source URL:
Class:
CONCEPT
Status:
Other
Class:
CONCEPT
